Getting your player ready...
Boulder-based N30 Pharmaceuticals Inc., a clinical-stage, biopharmaceutical company focused on treatments for cystic fibrosis, has raised $30 million in a mezzanine round of financing.
Proceeds from the financing will primarily be used to advance the company’s clinical trial program for N91115, a compound for the treatment of cystic fibrosis.
New investors Wellington Management, RA Capital Management LLC, Jennison Associates LLC, Rock Springs Capital Management LP, and Sabby Management LLC, will join existing investor, Deerfield Management Company LP.
